Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727477 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL30727482 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL1679795 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL30435700 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL31143600 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL14283383 | 0.92 | PDE5A (0.69) | PDE5A | |
| SCHEMBL28912195 | 0.92 | PDE5A (0.72) | PDE5A | |
| SCHEMBL28417919 | 0.91 | PDE5A (0.71) | PDE5A | |
| SCHEMBL28417910 | 0.91 | PDE5A (0.71) | PDE5A | |
| SCHEMBL17283017 | 0.91 | PDE5A (0.62) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430591-A | Synthesis method of avanafil | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-117430591-A | Synthesis method of avanafil | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-113917027-B | Optical isomer separation detection method of avanafil and intermediate thereof | 山东省药学科学院 | 2023-03-21 | — | — | CN | disclosed |
| CN-113917027-A | Optical isomer separation detection method for avanafil and intermediate thereof | 山东省药学科学院 | 2022-01-11 | — | — | CN | disclosed |
| CN-104356115-B | A kind of preparation method of 4-[(3-chloro-4-methoxy benzyl) amino]-2-[2-(methylol)-1-pyrrolidinyl] pyrimidine-5-carboxylic acid's ethyl ester | 齐鲁天和惠世制药有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-7927623-B2 | Pleasant taste; bioabsorbable; overcoated water insoluble drug in alcohol solvent and water soluble binder; mixing, compression | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-04-19 | — | — | US | disclosed |
| EP-1366760-B1 | TABLETS QUICKLY DISINTEGRATED IN ORAL CAVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-7501409-B2 | Preparations for oral administration | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-20040109890-A1 | Tablets quickly disintegrated in oral cavity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-10 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | disclosed |
| EP-1366760-A1 | TABLETS QUICKLY DISINTEGRATED IN ORAL CAVITY | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030195220-A1 | A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1316316-A1 | PREPARATIONS FOR ORAL ADMINISTRATION | TANABE SEIYAKU CO., LTD. (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | PDE3A, PDE3B, PDE2A | PDE5A 4/4885 |
| US-20030229095-A1 | Sexual disorders | PDE3B, PDE3A, PDE2A | PDE5A 4/4885 |
| US-20030195220-A1 | A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction | PDE5A, PDE3A, PDE2A | PDE5A 1/4885 |
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | PDE5A 2/4885 |
| US-20040109890-A1 | Tablets quickly disintegrated in oral cavity | SI, TAS2R60, TAS2R30 | PDE5A 1694/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | PDE5A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.